5.54
+0.01(+0.18%)
Currency In USD
| Previous Close | 5.53 |
| Open | 5.51 |
| Day High | 5.67 |
| Day Low | 5.46 |
| 52-Week High | 6.51 |
| 52-Week Low | 3.38 |
| Volume | 2.88M |
| Average Volume | 3.46M |
| Market Cap | 1.7B |
| PE | 55.4 |
| EPS | 0.1 |
| Moving Average 50 Days | 5.75 |
| Moving Average 200 Days | 4.92 |
| Change | 0.01 |
If you invested $1000 in MannKind Corporation (MNKD) 10 years ago, it would be worth $1,108 as of February 21, 2026 at a share price of $5.54. Whereas If you bought $1000 worth of MannKind Corporation (MNKD) shares 5 years ago, it would be worth $985.77 as of February 21, 2026 at a share price of $5.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 19, 2026 2:00 PM GMT
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share business updates during the Oppen
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 18, 2026 2:00 PM GMT
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiom
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
GlobeNewswire Inc.
Feb 09, 2026 11:05 AM GMT
Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to <18 years recently diagnosed with T1DDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasd